PL3663292T3 - Pochodna difenylometanu w postaci krystalicznej - Google Patents

Pochodna difenylometanu w postaci krystalicznej

Info

Publication number
PL3663292T3
PL3663292T3 PL20152959T PL20152959T PL3663292T3 PL 3663292 T3 PL3663292 T3 PL 3663292T3 PL 20152959 T PL20152959 T PL 20152959T PL 20152959 T PL20152959 T PL 20152959T PL 3663292 T3 PL3663292 T3 PL 3663292T3
Authority
PL
Poland
Prior art keywords
crystalline form
diphenylmethane derivative
diphenylmethane
derivative
crystalline
Prior art date
Application number
PL20152959T
Other languages
English (en)
Inventor
Hee-Kyoon Yoon
Se-Hwan Park
Ji-Sung Yoon
Soongyu Choi
Hee Jeong Seo
Eun-Jung Park
Younggyu Kong
Kwang-Seop Song
Min Ju Kim
So Ok PARK
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3663292(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co., Ltd., Green Cross Corporation filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of PL3663292T3 publication Critical patent/PL3663292T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20152959T 2016-06-17 2017-06-15 Pochodna difenylometanu w postaci krystalicznej PL3663292T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
EP17813615.6A EP3473621B1 (en) 2016-06-17 2017-06-15 Method for producing diphenylmethane derivative
EP20152959.1A EP3663292B1 (en) 2016-06-17 2017-06-15 Diphenylmethane derivative in crystalline form
PCT/KR2017/006271 WO2017217792A1 (ko) 2016-06-17 2017-06-15 다이페닐메탄 유도체의 제조방법

Publications (1)

Publication Number Publication Date
PL3663292T3 true PL3663292T3 (pl) 2022-01-17

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20152959T PL3663292T3 (pl) 2016-06-17 2017-06-15 Pochodna difenylometanu w postaci krystalicznej
PL17813615T PL3473621T3 (pl) 2016-06-17 2017-06-15 Sposób wytwarzania pochodnej difenylometanu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17813615T PL3473621T3 (pl) 2016-06-17 2017-06-15 Sposób wytwarzania pochodnej difenylometanu

Country Status (29)

Country Link
US (2) US10640496B2 (pl)
EP (2) EP3663292B1 (pl)
JP (4) JP6763978B2 (pl)
KR (2) KR102233229B1 (pl)
CN (2) CN109311861B (pl)
AU (1) AU2017285813B2 (pl)
CA (2) CA3026756C (pl)
CL (1) CL2018003645A1 (pl)
CO (1) CO2018014018A2 (pl)
DK (2) DK3663292T3 (pl)
DO (1) DOP2018000287A (pl)
EC (1) ECSP19000185A (pl)
ES (2) ES2898336T3 (pl)
HR (1) HRP20211670T8 (pl)
HU (1) HUE056428T2 (pl)
MA (2) MA44545B2 (pl)
MX (2) MX392177B (pl)
MY (1) MY203941A (pl)
NZ (1) NZ749398A (pl)
PE (2) PE20240590A1 (pl)
PH (1) PH12018550206A1 (pl)
PL (2) PL3663292T3 (pl)
PT (2) PT3473621T (pl)
RS (1) RS62550B1 (pl)
SA (2) SA521422474B1 (pl)
SG (2) SG11201811154QA (pl)
SI (1) SI3663292T1 (pl)
TN (1) TN2018000437A1 (pl)
WO (1) WO2017217792A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
BR112021002523A2 (pt) 2018-08-13 2021-05-04 Daewoong Pharmaceutical Co., Ltd. método para preparar um composto
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
AU2021225706B2 (en) 2020-02-27 2024-06-13 Daewoong Pharmaceutical Co., Ltd. Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same
US12448360B2 (en) * 2020-09-10 2025-10-21 Daewoong Pharmaceutical Co., Ltd. Synthesis method for preparing SGLT inhibitor intermediate
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
KR20230046784A (ko) * 2021-09-30 2023-04-06 주식회사 대웅제약 이나보글리플로진을 포함하는 약학 조성물
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
KR20240045138A (ko) 2022-09-29 2024-04-05 주식회사 대웅제약 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물
KR20240047952A (ko) 2022-10-05 2024-04-12 주식회사 대웅제약 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물
AU2023412900A1 (en) 2022-12-21 2025-06-12 Daewoong Therapeutics Inc. Eye drop-type pharmaceutical composition containing envogliflozin
KR20240107660A (ko) 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
RS53365B (sr) * 2003-08-01 2014-10-31 Mitsubishi Tanabe Pharma Corporation Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma
UA107175C2 (uk) 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
EP2350088A1 (en) 2008-07-30 2011-08-03 Ferrer Internacional, S.A. 1,6-dihydro-2h-3-oxa-6-aza-as-indacene compounds
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN103596564B (zh) * 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
BR112018076243A2 (pt) 2019-03-26
JP7352509B2 (ja) 2023-09-28
PE20190467A1 (es) 2019-04-04
CA3026756A1 (en) 2017-12-21
MA44545B1 (fr) 2020-05-29
AU2017285813A1 (en) 2019-01-17
HRP20211670T1 (hr) 2022-02-18
CN113651803A (zh) 2021-11-16
KR102379584B1 (ko) 2022-03-29
CN109311861B (zh) 2021-08-24
SG10201911782RA (en) 2020-02-27
TN2018000437A1 (en) 2020-06-15
MA44545B2 (fr) 2020-11-30
PT3473621T (pt) 2021-10-04
JP6763978B2 (ja) 2020-09-30
EP3663292B1 (en) 2021-09-01
CA3026756C (en) 2021-03-02
MX392177B (es) 2025-03-19
DOP2018000287A (es) 2019-03-31
RS62550B1 (sr) 2021-12-31
HRP20211670T8 (hr) 2022-03-18
DK3663292T3 (da) 2021-10-25
MA44545A1 (fr) 2019-10-31
PH12018550206A1 (en) 2019-09-30
WO2017217792A1 (ko) 2017-12-21
CA3081033A1 (en) 2017-12-21
RU2019101056A3 (pl) 2020-07-17
MA50774B1 (fr) 2022-02-28
RU2021129636A (ru) 2021-11-22
JP2023145481A (ja) 2023-10-11
SG11201811154QA (en) 2019-01-30
MX2018015647A (es) 2019-04-11
CA3081033C (en) 2022-04-12
NZ749398A (en) 2020-01-31
JP2019521985A (ja) 2019-08-08
US20190382390A1 (en) 2019-12-19
KR102233229B1 (ko) 2021-03-29
SI3663292T1 (sl) 2022-01-31
RU2019101056A (ru) 2020-07-17
HUE056428T2 (hu) 2022-02-28
US20190169174A1 (en) 2019-06-06
SA518400666B1 (ar) 2021-11-30
PE20240590A1 (es) 2024-03-21
PT3663292T (pt) 2021-11-08
AU2017285813B2 (en) 2020-02-06
CO2018014018A2 (es) 2019-03-08
MX385640B (es) 2025-03-18
SA521422474B1 (ar) 2023-11-02
US10889574B2 (en) 2021-01-12
JP7773506B2 (ja) 2025-11-19
US10640496B2 (en) 2020-05-05
ECSP19000185A (es) 2019-01-31
CL2018003645A1 (es) 2019-03-22
JP2020117528A (ja) 2020-08-06
EP3473621A1 (en) 2019-04-24
ES2891825T3 (es) 2022-01-31
ES2898336T3 (es) 2022-03-07
PL3473621T3 (pl) 2022-01-10
EP3663292A1 (en) 2020-06-10
MX2021008988A (es) 2022-05-05
JP2021152054A (ja) 2021-09-30
JP7669206B2 (ja) 2025-04-28
KR20210036892A (ko) 2021-04-05
EP3473621B1 (en) 2021-08-04
MY203941A (en) 2024-07-25
MA50774A1 (fr) 2021-03-31
DK3473621T3 (da) 2021-09-06
KR20170142904A (ko) 2017-12-28
CN109311861A (zh) 2019-02-05
CN113651803B (zh) 2022-10-28
EP3473621A4 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
PL3663292T3 (pl) Pochodna difenylometanu w postaci krystalicznej
ZA201704602B (en) Dihydroindolizinone derivative
PL3040176T3 (pl) Instalacja produkcyjna
GB201419174D0 (en) Crystalline forms
GB201409650D0 (en) Manufacturing methods
IL265445A (en) crystalline forms
IL248772A0 (en) A consequence of cyclohexyl pyridine
LT3390358T (lt) Kristalinis eravaciklino bis-hidrochloridas
PL3350179T3 (pl) Krystaliczne postacie
ZA201700664B (en) Azole benzene derivative and crystalline form thereof
GB201508232D0 (en) Box cutter structure
ZA201902553B (en) Crystalline forms
IL261795A (en) Crystalline form
IL251471B (en) A method for producing a derivative of 3- aryloxyquinoline
GB201403323D0 (en) No Title supplied
GB201607666D0 (en) Sleeping accommodation
GB201605320D0 (en) Sleeping accommodation
GB201601651D0 (en) Sleeping accommodation
TWM489062U (en) Tool box structure
PH32015000431S1 (en) Multi-purpose box
AU2015903233A0 (en) Improvements in bedding
GB201404967D0 (en) X-System 7
GB201404770D0 (en) X-system 7
AU2015902784A0 (en) Improvements in Bedding
GB201505132D0 (en) Box cutter structure